- medical treatment of breast cancer
- adjuvant chemotherapy for early breast cancer
- endocrine therapies
- treatment of advanced/metastatic breast cancer
- novel targeted therapies
Stephen Johnston is Professor of Breast Cancer Medicine and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. He was the first Director of the UK’s National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden from 2007 to 2012, and is currently Clinical Director of the Breast, Lung and AOS Clinical Business Unit at The Royal Marsden.
He graduated in 1983 from Trinity College at the Cambridge University, and in 1986 from the Medical School at the University of Newcastle-upon- Tyne. He trained in general medicine at St Bartholomew's Hospital and Hammersmith Hospital in London, and subsequently in medical oncology at The Royal Marsden. He gained his PhD from The Institute of Cancer Research at the University of London, and took up his current position as Consultant Medical Oncologist in the Breast Unit at The Royal Marsden in 1997.
He has a specialist interest in the treatment of metastatic breast cancer, and his major research interests lie in understanding mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research, and is chief investigator of several phase II/III trials of novel therapeutic approaches in advanced disease, including new endocrine therapies and targeted signal transduction inhibitors.
He has published over 250 breast cancer related articles in peer-reviewed journals, and is a regular invited lecturer at national and international meetings. He is a member of several scientific committees and advisory boards, a prior Faculty member at the American Society for Clinical Oncology, a current member of San Antonio Breast Cancer Symposium abstract review committee, and serves as Deputy/Associate Editor for the international journals ‘Breast Cancer Research’ and ‘Clinical Breast Cancer’.